Last reviewed · How we verify
Artemether-lumefantrine fixed combination
Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway.
Artemether is a fast-acting antimalarial that acts by inhibiting the parasite's mitochondrial electron transport chain, while lumefantrine is a slow-acting antimalarial that acts by inhibiting the parasite's heme detoxification pathway. Used for Malaria.
At a glance
| Generic name | Artemether-lumefantrine fixed combination |
|---|---|
| Also known as | Coartem Novartis |
| Sponsor | Epicentre |
| Drug class | Antimalarial |
| Target | Mitochondrial electron transport chain, Heme detoxification pathway |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Artemether-lumefantrine is a combination therapy used to treat malaria. Artemether works quickly to kill the parasite, while lumefantrine works more slowly to prevent the parasite from developing resistance.
Approved indications
- Malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia) (PHASE3)
- Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam (PHASE3)
- Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy (PHASE3)
- Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients (PHASE3)
- Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Artemether-lumefantrine fixed combination CI brief — competitive landscape report
- Artemether-lumefantrine fixed combination updates RSS · CI watch RSS
- Epicentre portfolio CI